Somewhat Favorable Media Coverage Somewhat Likely to Impact Uroplasty (UPI) Share Price

News articles about Uroplasty (NYSE:UPI) have trended somewhat positive on Saturday, AlphaOne reports. The research firm, a service of Accern, identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. AlphaOne ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Uroplasty earned a media sentiment score of 0.06 on AlphaOne’s scale. AlphaOne also gave news headlines about the medical device company an impact score of 51 out of 100, meaning that recent media coverage is somewhat likely to have an impact on the stock’s share price in the next several days.

Shares of Uroplasty (NYSE:UPI) traded up 0% during midday trading on Friday, hitting $1. Uroplasty has a 52 week low of $1.00 and a 52 week high of $4.00. The company’s 50-day moving average price is $1.00 and its 200 day moving average price is $2.00.

WARNING: This article was reported by Markets Daily and is owned by of Markets Daily. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.themarketsdaily.com/2017/05/20/uroplasty-upi-earns-news-impact-score-of-0-06-updated.html.

About Uroplasty

Cogentix Medical, Inc (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover.

12 Month Chart for NYSE:UPI

Receive News & Ratings for Uroplasty Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply